Canaccord Genuity Maintains Buy on Helus Pharma, Lowers Price Target to $42

Canaccord Genuity analyst Sumant Kulkarni maintains Helus Pharma (NASDAQ: HELP ) with a Buy and lowers the price target from $45 to $42.